In these studies, we reported on the prevalence of pathogenic BRCA1/2 germline mutation and the identification of 4 small-scale founder mutations and 1 large deletion, 2 in BRCA1 (HGVS/BIC: c.3331_3334delCAAG/3450del4 and c.5123C>A/A1708E) and 3 in BRCA2 (c.1763_1766delATAA/1991del4, c.2808_2811delACAA/-3034del4, and ex1-14del), which accounted for 89% and 44% of all BRCA1 and BRCA2 mutations, respectively.11,12 The overall prevalence of BRCA1/2 mutations was 16% in families with multiple female cases of BC and 21% in families affected by both breast and OC. This evidence concerns the gene BRCA2 and breast cancer.